Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
107 hedge funds and large institutions have $163M invested in Eagle Pharmaceuticals, Inc. in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 48 reducing their positions, and 31 closing their positions.
5% more call options, than puts
Call options by funds: $22K | Put options by funds: $21K
15% less funds holding
Funds holding: 126 → 107 (-19)
22% less capital invested
Capital invested by funds: $209M → $163M (-$46.6M)
35% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 48
61% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$5.27M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.8M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.56M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.38M |
| 5 |
Millennium Management
New York
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.18M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.15M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.82M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.53M |
| 5 |
E
Ergoteles
New York
|
-$1.35M |
EGRX Hedge Fund Activity: Q3 2023 in Review
107 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2023, worth a combined $163M — down 22% from $209M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of EGRX and 12 opened new positions — a net loss of 19 holders — while 48 trimmed existing stakes and 31 added.
The largest buyer was Brandes Investment Partners, adding an estimated $5.27M. The largest seller was BlackRock, cutting an estimated $2.18M.
- 107 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2023, down from 126 in Q2 2023.
- Funds reported $163M of Eagle Pharmaceuticals, Inc. stock for Q3 2023, down 22% quarter-over-quarter.
- 12 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2023 and 31 closed out, a net change of -19 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2023 was Brandes Investment Partners, an estimated $5.27M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2023 was BlackRock, an estimated $2.18M sold.
Based on aggregated 13F filings for Q3 2023.